Arcturus Therapeutics Holdings Inc. (ARCT), a commercial mRNA medicines and vaccines company, has a clinical trial catalyst to watch next week.The company is scheduled to report interim data from its phase II trials of its investigational therapy ARCT-810 in participants with Ornithine Transcarbamylase (OTC) deficiency on June 30, 2025.Ornithine transcarbamylase (OTC) deficiency, caused by mutatio...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.